Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
This is a phase 1b, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.
创建时间：
2021-08-15
相关数据集
暂无相关数据集
